Novelion Therapeutics's revenue for the
three
months ended in Mar. 2019 was €28.5 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2019 was €117.6 Mil.
Novelion Therapeutics's Revenue per Share for the
three
months ended in Mar. 2019 was €1.54.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2019 was €6.35.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Novelion Therapeutics's Revenue
For the Biotechnology subindustry, Novelion Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novelion Therapeutics's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novelion Therapeutics's Revenue distribution charts can be found below:
* The bar in red indicates where Novelion Therapeutics's Revenue falls into.
Novelion Therapeutics Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was €117.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Novelion Therapeutics Revenue Related Terms
Thank you for viewing the detailed overview of Novelion Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Novelion Therapeutics (STU:QLTA) Business Description
Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:QLTA has been successfully added to your 